First Patient Dosed in U.S. Expanded Access Program for TLX250-CDx, Telix's Breakthrough Kidney Cancer Imaging Agent

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a United States (U.S.) expanded access program (EAP, ClinicalTrials.gov ID: NCT06090331) for TLX250-CDx (89Zr-DFO-girentuximab). TLX250-CDx is the Company's first-in-class, non-invasive investigational positron emission tomography (PET) imaging agent in clear cell renal cell carcinoma (ccRCC).

Related Keywords

United States ,Switzerland ,Melbourne ,Victoria ,Australia ,United Kingdom ,Canada ,Belgium ,Japan ,Australian ,Mary Jessel ,Kyahn Williamson ,John Leahy ,Drug Administration ,Health Canada ,Corporate Communications ,Telix Pharmaceuticals ,Australian Therapeutic Goods Administration ,Imaging At Austin Radiological Association In ,Global Medical Affairs At Telix ,Australian Securities Exchange ,Austin Radiological Association ,Principal Investigator ,Senior Vice President ,Global Medical Affairs ,Biologics License Application ,Offering Compassionate Use ,Investigational Medicines ,European Economic Area ,Telix Pharmaceuticals Limited ,Yap ,Felix ,Food And Drug Administration ,